Wednesday, April 27, 2016 4:25:34 PM
April 27, 2016
Click For Healio.com Article
Phase 3 study results presented at the American Society of Addiction Medicine annual conference indicated efficacy of Probuphine, a 6-month subdermal buprenorphine implant, for long-term maintenance treatment of opioid addiction.
“This was the first head-to-head comparison study of Probuphine and sublingual buprenorphine, demonstrating the efficacy of a long acting 6-month buprenorphine implant,” study researcher Richard N. Rosenthal, MD, of the Icahn School of Medicine at Mount Sinai, said in a press release. “The study results show that participants in the implant group sustained clinical stability over the course of 6 months. The implant group was also more likely to remain free from illicit opioids at 85.7% compared to 71.9% of those maintained on sublingual buprenorphine. If approved, Probuphine could help expand access to medication to treat opioid use disorders, providing people with a new option.”
To assess efficacy and safety of Probuphine (buprenorphine, Titan Pharmaceuticals Inc.), researchers conducted a double-blind, double-dummy, multisite study among 177 adults with opioid dependence who were clinically stabilized for at least 3 months on 8 mg or more of sublingual buprenorphine.
Participants were randomly assigned to receive daily sublingual buprenorphine tablets at their previous maintenance dose and four placebo implants or daily sublingual buprenorphine tablets plus four long-acting buprenorphine implants. The intent-to-treat population included 173 participants, of which 84 received long-acting buprenorphine implants. Following implantation, participants provided urine samples at six scheduled monthly visits and four randomly assigned visits.
Analysis indicated a responder rate of 87.6% in the sublingual buprenorphine group and 96.4% in the buprenorphine implants group.
Further, results indicated statistically significant superiority for buprenorphine implants vs. sublingual buprenorphine (P = .034).
Illicit opioid use occurred in 28.1% of the sublingual buprenorphine group and 14.3% of the buprenorphine implants group.
One participant in the buprenorphine implants group discontinued due to muscle spasms. There were no discontinuations in the sublingual buprenorphine group.
Severe adverse events occurred in 10.1% of the sublingual buprenorphine and 3.4% of the buprenorphine implants group (P > 0.05).
Treatment-emergent adverse events of any severity occurred in 6.7% of the sublingual buprenorphine group and 16.1% of the buprenorphine implants group (P > 0.05).
“Like any chronic disease, the ability to personalize treatment is key to long-term success and quality of life for opioid dependent individuals,” Frank J. Vocci, PhD, president and senior research scientist at Friends Research Institute. “The data presented today on Probuphine provides hope for a new option that could address critical issues like medication compliance and the risks of oral buprenorphine.”
Probuphine is currently under final review by the FDA following a 12 to 5 vote by the FDA’s Psychopharmacologic Drugs Advisory Committee in favor of approving the treatment in January 2016.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM